Top > Search of International Patents > Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells

Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells

Foreign code F110003664
File No. A261-09WO
Posted date Jun 30, 2011
Country EPO
Application number 07851040
Gazette No. 2098246
Gazette No. 2098246
Date of filing Dec 21, 2007
Gazette Date Sep 9, 2009
Gazette Date Jun 28, 2017
International application number JP2007074634
International publication number WO2008078673
Date of international filing Dec 21, 2007
Date of international publication Jul 3, 2008
Priority data
  • P2006-349458 (Dec 26, 2006) JP
  • 2007WO-JP74634 (Dec 21, 2007) WO
Title Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells
Abstract (EP2098246)
The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine.
The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting The CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.
Scope of claims [claim1]
1. An in vitro screening method for screening a substance capable of increasing proliferation and survival of B cells in an early stage of the immune response, wherein the method is based on determining the degree of inhibition of the expression of the CD22 gene in IgM and IgD positive naive B cells, wherein said method comprises the following steps: (a) contacting, in vitro, a substance to be screened with IgM and IgD positive naive B cells; (b) detecting the degree of inhibition of the expression of the CD22 gene in said cells; and (c) selecting a substance which inhibits said expression, and wherein the early stage of the immune response is from the first to the seventh day after an immunization.
[claim2]
2. A non-therapeutic method for screening a substance capable of increasing proliferation and survival of B cells in an early stage of the immune response, wherein the method is based on determining the degree of inhibition of the expression of the CD22 gene in IgM and IgD positive naive B cells, wherein said method comprises the following steps: (a) contacting a substance to be screened with IgM and IgD positive naive B cells; (b) detecting the degree of inhibition of the expression of the CD22 gene in said cells; and (c) selecting a substance which inhibits said expression, wherein the early stage of the immune response is from the first to the seventh day after an immunization,
and wherein if said method is carried out in vivo, the subject is non-human.
[claim3]
3. A method according to Claim 1 or 2, wherein the early stage of the immune response is from the third to fifth day after an immunization.
[claim4]
4. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises the increase of proliferation, division and/or survival of the B cells in the early stage of the immune response.
[claim5]
5. A method according to Claim 4, wherein the B cells proliferate and/or divide into IgG1 **+ B cells, IgM **+ B cells and germinal center B cells.
[claim6]
6. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises class switching and/or differentiation of the B cells in an earlier stage.
[claim7]
7. A method according to Claim 6, wherein the class switching is that to IgG1 **+ positive cells and/or the differentiation is that into antibody-producing cells or germinal center B cells.
[claim8]
8. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises an increase in the number of antibody-producing cells and in the amount of antibodies produced and/or the production of antibodies in an earlier stage.
[claim9]
9. A method according to any one of Claims 1 to 8, wherein the expression of the CD22 gene is repressed at a transcriptional level.
[claim10]
10. A method according to any one of Claims 1 to 8, wherein said inhibition is related to the promotion of signal transduction of B cell receptor.
  • Applicant
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • Inventor
  • TSUBATA TAKESHI
  • ONODERA TAISHI
IPC(International Patent Classification)
Reference ( R and D project ) CREST Clarification of the Biological Functions of Sugar Chains and the Use of this Knowledge in Applied Technologies AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close